Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For type 2 diabetes mellitus. Sold as Victoza, Saxenda. Every FDA application for this active ingredient: 2 branded and 11 generic.
As of Nov 15, 2026, FDA lists 13 applications for Liraglutide (sold as Victoza, Saxenda), first approved Jan 25, 2010, with 10 new uses approved and 0 published complete response letters.
First approved: Jan 25, 2010
Applications: 13
New uses approved: 10
Complete response letters: 0
Medicare spending, 2025: $100M
First approved in the EU: Jun 30, 2009
First approved in Japan: Jan 20, 2010
Shortage: Current
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan the same month as the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
VictozaA drug with a new dosage and other characteristics indicated for the treatment of type 2 diabetes mellitus. · Novo Nordisk Pharma Ltd. · May 22, 2019
VictozaA drug with a new indication for the treatment of type 2 diabetes mellitus. · Novo Nordisk Pharma Ltd. · Aug 29, 2014
Victoza, new ingredientA drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to… · Novo Nordisk Pharma Ltd. · Jan 20, 2010 · Review report
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Hikma
Lupin
Fresenius Kabi USA
Sandoz